Clinical

Articles

AstraZeneca’s leading diabetes medication could be approved to treat chronic kidney disease for patients with and without type 2 diabetes.

Diabetes med Farxiga nabs FDA Priority Review for Chronic Kidney Disease

Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.

Two metformin products recalled, more on the way

How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.

Pharma exec: New type 2 diabetes treatment competitively priced

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

FDA clears first ready-to-use insulin for IV infusion

FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

FDA fast tracks blockbuster diabetes drug for heart failure

FDA fast-tracks biosimiliar insulin products to elevate competition.

Lack of insulin competition high priority for FDA

Eli Lilly launches generic insulin ahead of Congressional hearings

FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.

FDA clears novel diabetes, tropical disease therapies

FDA approves first long-term implantable glucose-monitoring system

Mayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.

Overtreating glucose levels can take a toll on diabetes patients

A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.

Wide geographic differences exist in treating diabetes

Study seeks to determine whether significant improvement in glycemic control can be achieved when regular coaching is part of the process.

Patient navigators can benefit diabetes outcomes

Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.

Pharma company keeps pace with rise of diabetes

A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.

3 ways to improve diabetes med adherence

Unhydrogenated, unsaturated vegetable oils, such as canola oil, can have health advantages when included in as part of a low-glycemic index (GI) diet in people with type 2 diabetes, according to research presented at American Diabetes Association Scientific Sessions in San Francisco, and published in Diabetes Care.

ADA: Canola oil can help control blood glucose in people with type 2 diabetes

Older adults with diabetes mellitus may be at increased risk for Alzheimer’s disease or vascular dementia following a hypoglycemic event, according to a study published online by JAMA Internal Medicine on June 10th.

Hypoglycemic event in elderly raises dementia risk

Forty-three members of Congress are urging the Centers for Medicare and Medicaid Services (CMS) not to implement a new policy that prohibits independent community pharmacies from providing same-day, home delivery of diabetes testing supplies (DTS) to homebound seniors.

Congressional coalition rallies against CMS ban on pharmacy home deliveries of diabetes testing supplies

Although the prevalence of diabetes mellitus in hospitalized patients remains unknown, an estimated one-fourth of inpatients experience hyperglycemia.1 Hyperglycemia is linked to poor health outcomes, and there is evidence that intensive glucose control in the hospital reduces mortality, need for dialysis, infections, and length of stay.2 The American Diabetes Association (ADA) publishes clinical practice guidelines annually, which offer clinicians, patients, researchers, and payers current, evidence-based recommendations on all components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The updated guidelines focus on changes in the recommendations for care of the hospitalized diabetes patient.

Standards of medical care in diabetes: focus on updated recommendations in hospitalized patients

On March 29, 2013, FDA approved canagliflozin (Invokana, Janssen Pharmaceuticals, Inc.), a once-daily tablet, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

New molecular entity: Canagliflozin

In November 2012, FDA approved tofacitinib (Xeljanz, Pfizer) 5 mg tablets for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have not had an adequate response to methotrexate or are intolerant to methotrexate. Tofacitinib, an oral non-biologic disease-modifying antirheumatic drug (DMARD) can be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. It is contraindicated for use with biologic DMARDs or with immunosuppressive agents, such as azathioprine and cyclosporine.

Diabetes and Endocrinology